Orgenesis (ORGS) 10-Q 15 Oct 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Aug. 31, 2014	Oct. 13, 2014
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Aug-14	'
Trading Symbol	'orgs	'
Entity Registrant Name	'Orgenesis Inc.	'
Entity Central Index Key	'0001460602	'
Current Fiscal Year End Date	'--11-30	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	55,172,617
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Well Known Seasoned Issuer	'No	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Aug. 31, 2014	Nov. 30, 2013
CURRENT ASSETS:	'	'
Cash and cash equivalents	$1,533,147	$50,827
Short-term bank deposit	10,002	10,002
Prepaid expenses and other account receivable	96,385	36,908
Total current assets	1,639,534	97,737
FUNDS IN RESPECT OF RETIREMENT BENEFITS OBLIGATION	4,842	3,630
PROPERTY AND EQUIPMENT, NET	15,729	12,854
Total assets	1,660,105	114,221
CURRENT LIABILITIES:	'	'
Short-term bank credit	13,896	0
Accounts payable	236,963	138,775
Accrued expenses	811,012	386,122
Related parties	42,362	42,362
Employees and related payables	488,290	155,100
Advance payment on account of grant	110,678	0
Convertible loans and accrued interest	2,614,770	264,050
Total current liabilities	4,317,971	986,409
LONG-TERM LIABILITIES:	'	'
Warrants liability	1,435,000	1,157,954
Retirement benefits obligation	5,421	4,272
Total long-term liabilities	1,440,421	1,162,226
Total liabilities	5,758,392	2,148,635
COMMITMENTS AND CONTINGENCIES	'	'
STOCKHOLDER'S EQUITY (DEFICIT):	'	'
Common stock, $0.0001 par value, 1,750,000 shares authorized, 55,172,617 (unaudited) and 51,144,621 shares issued and outstanding as of August 31, 2014 (unaudited) and November 30, 2013, respectively	5,517	5,114
Additional paid-in capital	12,568,738	8,635,447
Accumulated deficit	-16,672,542	-10,674,975
Total stockholders' (deficit)	-4,098,287	-2,034,414
Total Liabilities net of Stockholders' deficiency	$1,660,105	$114,221

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS PARENTHETICALS (USD $)	Aug. 31, 2014	Nov. 30, 2013
Common Stock, par or stated value	$0.00	$0.00
Common Stock, shares authorized	1,750,000	1,750,000
Common Stock, shares issued	55,172,617	51,144,621
Common Stock, shares outstanding	55,172,617	51,144,621

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (USD $)	3 Months Ended		9 Months Ended
	Aug. 31, 2014	Aug. 31, 2013	Aug. 31, 2014	Aug. 31, 2013
REVENUE	$0	$0	$0	$0
OPERATING EXPENSES:	'	'	'	'
Research and development	845,599	226,935	1,936,079	930,487
General and administrative	440,058	935,228	2,032,073	2,844,350
Total operating expenses	1,285,657	1,162,163	3,968,152	3,774,837
OPERATING LOSS	-1,285,657	-1,162,163	-3,968,152	-3,774,837
Financial expenses (income), net	-2,206,588	224,723	-2,029,415	-49,046
Total other expense	-2,206,588	224,723	-2,029,415	-49,046
NET LOSS	($3,492,245)	($937,440)	($5,997,567)	($3,823,883)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - Basic and diluted	54,916,980	51,144,621	53,672,820	50,264,348
NET LOSS PER SHARE - Basic and diluted	($0.06)	($0.02)	($0.11)	($0.08)

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' CAPITAL EQUITY/DEFICIENCY (USD $)	Common Stock [Member]	Additional paid-in capital [Member]	Accumulated Deficit [Member]	Total
Beginning Balance at Nov. 30, 2013	$5,114	$8,635,447	($10,674,975)	($2,034,414)
Beginning Balance (Shares) at Nov. 30, 2013	51,144,621	'	'	'
Stock based compensation related to options granted to employees	'	1,076,428	'	1,076,428
Stock-based compensation related to options granted to consultants	'	901,733	'	901,733
Issuance of shares and warrants	210	1,094,196	'	1,094,406
Issuance of shares and warrants (Shares)	2,095,013	'	'	'
Conversions of convertible loans into shares and warrants	71	630,432	'	630,503
Conversions of convertible loans into shares and warrants (Shares)	713,023	'	'	'
Issuance of shares along with convertible loan	50	179,950	'	180,000
Issuance of shares along with convertible loan (Shares)	500,000	'	'	'
Exercise of stock options into shares	62	562	'	624
Exercise of stock options into shares (Shares)	623,806	'	'	'
Exercise of warrants into shares and warrants	10	49,990	'	50,000
Exercise of warrants into shares and warrants (Shares)	96,154	'	'	'
Net loss	'	'	-5,997,567	-5,997,567
Ending Balance at Aug. 31, 2014	$5,517	$12,568,738	($16,672,542)	($4,098,287)
Ending Balance (Shares) at Aug. 31, 2014	55,172,617	'	'	'

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
	Aug. 31, 2014	Aug. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'
Net income (loss)	($5,997,567)	($3,823,883)
Adjustments to reconcile net income to net cash used in operating activities:	'	'
Stock-based compensation related to options granted to employees	1,076,428	1,882,761
Stock-based compensation related to options granted to consultants	901,733	242,161
Receipt on account of shares to be issued to consultant on account of services	0	6,144
Increase in accrued severance pay	1,149	1,922
Depreciation expense	2,589	2,404
Change in fair value of warrants and embedded derivative	1,291,046	-51,802
Financial expense on convertible loans and funding fees	682,223	73,525
Changes in operating assets and liabilities:	'	'
Increase in prepaid expenses and other accounts receivable	-59,477	-12,621
Increase in accounts payable	135,594	15,552
Increase in accrued expenses	424,890	93,889
Increase in employee and related party payables	333,190	45,435
Increase in advance payment on account of grant	110,678	0
Net cash used in operating activities	-1,097,524	-1,524,513
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'
Purchase of property and equipment	-5,464	-7,839
Amounts funded in respect of retirement benefits obligation	-1,212	-1,561
Other	0	0
Net cash used in investing activities	-6,676	-9,400
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'
Short-term bank credit	13,896	0
Proceeds from issuance of shares and warrant	922,000	1,800,000
Proceeds from exercise of stock options	624	0
Proceeds from exercise of warrants into shares and warrants	50,000	0
Proceeds from loan received	100,000	250,000
Proceeds from issuance of convertible loan together with shares	1,500,000	0
Net cash provided by financing activities	2,586,520	2,050,000
NET CHANGE IN CASH	1,482,320	516,087
CASH AT BEGINNING OF PERIOD	50,827	347
CASH AT END OF PERIOD	1,533,147	516,434
Cash paid during the period for:	'	'
Interest	0	0
Income taxes	0	0
Non-cash investing and financing activities:	'	'
Common stock issued for rended services	37,406	0
Common stock issued for converstion of loans and accrued interest	$370,772	$0

GENERAL_AND_BASIS_OF_PRESENTAT

GENERAL AND BASIS OF PRESENTATION	9 Months Ended
	Aug. 31, 2014
GENERAL AND BASIS OF PRESENTATION [Text Block]	'
	NOTE 1 — GENERAL AND BASIS OF PRESENTATION
	Orgenesis, Inc. (the “Company”), incorporated in the State of Nevada on June 5, 2008, is engaged, together with its subsidiaries, in the research and development of a new technology for regeneration of functional insulin-producing cells, thus, enabling normal glucose regulated insulin secretion, via cell therapy.
	These unaudited condensed consolidated financial statements of the Company and its wholly-owned subsidiaries have been prepared in accordance with U.S. GAAP and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial statements. Accordingly, they do not contain all information and notes required by U.S. GAAP for annual financial statements. In the opinion of management, the unaudited condensed consolidated interim financial statements reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of the Company’s consolidated financial position as of August 31, 2014, the consolidated results of operations and comprehensive loss for the three and nine-month periods ended August 31, 2014 and 2013, and the consolidated cash flows for the nine-month periods ended August 31, 2014 and 2013.
	The financial data and other information disclosed in the notes to the condensed consolidated financial statements related to these periods are unaudited. The results for the three and nine-month periods ended August 31, 2014 are not necessarily indicative of the results to be expected for the year ending November 30, 2014.
	These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended November 30, 2013. The condensed consolidated balance sheet data as of November 30, 2013 was derived from the audited consolidated financial statements for the year ended November 30, 2013, but does not include all disclosures required by U.S. GAAP.
	In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-10, “Development Stage Entities (Topic 915), Elimination of Certain Financial Reporting Requirements, including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation” (“ASU 2014-10”). The amendments in ASU 2014-10 remove the definition of a development stage entity from the Master Glossary of the Accounting Standards Codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from accounting principles generally accepted in the United States of America (“U.S. GAAP”). In addition, the amendments eliminate the requirements for development stage entities to: (i) present inception-to-date information in the statements of income, cash flows, and shareholder equity; (ii) label the financial statements as those of a development stage entity; (iii) disclose a description of the development stage activities in which the entity is engaged; and (iv) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The presentation and disclosure requirements in Accounting Standard Codification (“ASC”) Topic 915, “Development Stage Entities” are no longer required for interim and annual reporting periods beginning after December 15, 2014. The revised consolidation standards will take effect in annual periods beginning after December 15, 2015. However, early adoption is permitted. The Company has elected to early adopt the provisions of ASU 2014-10 for these unaudited condensed consolidated financial statements.
	In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements— Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. Continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. Currently, there is no guidance under U.S. GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. The amendments in this Update provide that guidance. In doing so, the amendments should reduce diversity in the timing and content of footnote disclosures. The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). For the period ended August 31, 2014, management evaluated the Company’s ability to continue as a going concern and concluded that substantial doubt has not been alleviated about the Company’s ability to continue as a going concern. While the Company continues to explore further significant sources of financing, management’s assessment was based on the uncertainty related to the amount and nature of such financing over the next twelve months.
	Going Concern
	These unaudited interim condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has accumulated losses since inception of $16,672,542, as well as negative cash flows from operating activities. Presently, the Company does not have sufficient cash resources to meet its plans in the twelve months following August 31, 2014. Management is in the process of evaluating various financing alternatives, as the Company will need to finance future research and development activities and general and administrative expenses in either the public or private equity markets. These factors raise substantial doubt about the Company’s ability to continue as a going concern.
	Management believes that it will be able to secure the necessary financing as a result of ongoing financing discussions with third party investors and existing shareholders. However, there is no assurance that the Company will be successful with those initiatives.
	These condensed consolidated financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent on its ability to obtain additional financing as may be required and ultimately to attain profitability. If the Company is unsuccessful in raising additional financing, it may need to curtail, discontinue or cease operations.

FAIR_VALUE_PRESENTATION

FAIR VALUE PRESENTATION	9 Months Ended
	Aug. 31, 2014
FAIR VALUE PRESENTATION [Text Block]	'
	NOTE 2 - FAIR VALUE PRESENTATION
	The fair value measurement guidance clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in the valuation of an asset or liability. It establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under the fair value measurement guidance are described below:
	Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets or liabilities;
	Level 2 - Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;
	Level 3 - Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).
	As of August 31, 2014, the Company’s assets and liabilities that are measured at fair value and classified as level 3 fair value are as follows:
			31-Aug-14
			Level 3			Total
	Warrants	$	1,435,000		$	1,435,000
	Embedded derivative*	$	1,588,000		$	1,588,000
			30-Nov-13
			Level 3			Total
	Warrants	$	1,157,954		$	1,157,954
	* The embedded derivative is presented in the Company's balance sheets on a combined basis with the related host contract (the convertible loans).
	The fair value of each of the warrants described in Note 6a is determined by using a Monte Carlo type valuation model based on a risk neutral approach. The model takes as an input the estimated future dates when new capital will be raised, and builds a multi-step dynamic model. The first step is to model the risk neutral distribution of the share value on the new issuance dates. Then for each path to use the Black-Scholes valuation model to estimate the value of the warrants on the last issuance date including all the changes in exercise price and quantity along this path. The significant unobservable input used in the fair value measurement is the future expected issuance dates.
	The fair value of the embedded derivative described in Note 5b is determined by using the Black-Scholes valuation model. Notwithstanding the anti-dilution provision as described in Note 5b the Black Scholes formula produces a value that is substantially the same to the value under more flexible option valuation models such as the Monte Carlo simulation model due to an ineffectiveness of this protection feature over the relatively short term of the embedded derivative.
	The following table presents the assumptions that were used for the models as of August 31, 2014:
							Embedded
				Warrants			Derivative
		Fair value of shares of common stock	$	0.9		$	0.9
		Expected volatility		90%			86%
		Risk free interest rate		0.03% - 0.12%			0.04%
		Expected term (years)		0.25 – 1.08			0.33
		Expected dividend yield		0%			0%
	The table below sets forth a summary of the changes in the fair value of the Company’s financial liabilities classified as Level 3 for the nine months ended August 31, 2014:
							Embedded
				Warrants			Derivative
		Balance at beginning of period	$	1,157,954		$	-
		Additions		-			574,000
		Changes in fair value during the period		277,046			1,014,000
		Balance at end of period	$	1,435,000		$	1,588,000

COMMITMENTS_AND_CONTINGENT_LIA

COMMITMENTS AND CONTINGENT LIABILITIES	9 Months Ended
	Aug. 31, 2014
COMMITMENTS AND CONTINGENT LIABILITIES [Text Block]	'
	NOTE 3 – COMMITMENTS AND CONTINGENT LIABILITIES
	a.	Tel Hashomer - Medical Research, Infrastructure and Services Ltd.
	On February 2, 2012, the Company’s Israeli subsidiary, Orgenesis Ltd. (the “Israeli Subsidiary”), entered into a licensing agreement with Tel Hashomer - Medical Research, Infrastructure and Services Ltd (the “Licensor”). According to the agreement, the Israeli Subsidiary was granted a worldwide royalty bearing an exclusive license to certain information regarding a molecular and cellular approach directed at converting liver cells into functional insulin producing cells as a treatment for diabetes.
	As consideration for the licensed information, the Israeli Subsidiary will pay the following to the Licensor:
		1)	A royalty of 3.5% of net sales;
		2)	16% of all sublicensing fees received;
		3)	An annual license fee of $15,000, which commenced on January 1, 2012 and shall be paid once every year thereafter (the “Annual Fee”). The Annual Fee is non-refundable, but it shall be credited each year due, against the royalty noted above, to the extent that such are payable, during that year; and
		4)	Milestone payments as follows:
		a)	$50,000 on the date of initiation of phase I clinical trials in human subjects;
		b)	$50,000 on the date of initiation of phase II clinical trials in human subjects;
		c)	$150,000 on the date of initiation of phase III clinical trials in human subjects; and
		d)	$750,000 on the date of initiation of issuance of an approval for marketing of the first product by the FDA.
		e)	$2,000,000, when worldwide net sales of Products have reached the amount of $150,000,000 for the first time, (The “Sales Milestone”).
	As of August 31, 2014 the Company has not reached any of these milestones.
	In the event of closing of an acquisition of all of the issued and outstanding share capital of the Israeli Subsidiary and/or consolidation of the Israeli Subsidiary or the Company into or with another corporation (“Exit”), the Licensor shall be entitled to choose whether to receive from the Company a one-time payment based, as applicable, on the value of either 5,563,809 shares of common stock of the Company at the time of the Exit or the value of 1,000 shares of common stock of the Israeli Subsidiary at the time of the Exit.
	On March 22, 2012, the Israeli Subsidiary entered into a research service agreement with the Licensor. According to the agreement, the Licensor will perform a study at the facilities and use the equipment and personnel of the Chaim Sheba Medical Center (the “Hospital”), for the consideration of approximately $74,000 for a year. On May 1, 2013, the Israeli Subsidiary renewed the research agreement for an annual consideration of approximately $92,000, and on May 4, 2014, the Israeli Subsidiary renewed the research agreement for an annual consideration of approximately $114,000.
	b.	Mintz, Levin, Ferris, Glovsky and Popeo, P.C.
	On February 2, 2012, the Company entered into an agreement with its patent attorneys, Mintz, Levin, Ferris, Glovsky and Popeo, P.C. (“Mintz Levin”) for professional services related to patent registration. In addition to an amount of $80,000 paid to Mintz Levin, the Company issued 1,390,952 shares of common stock that will be held in escrow for two years. As a result of the escrow, the fair value of these shares issued for services were $509,622 based on a 34.57% discount calculated on the price per share on February 2, 2012. The Company will pay additional $50,000 upon consummation of the earlier of:
		1)	The purchase of all the Company’s common stock and/or amalgamation of the Company or its subsidiary into or with another corporation.
		2)	The Company sublicensing the technology to a non-affiliate of the Company.
		3)	$20,000 upon each of the following milestones (but in any event no more than $50,000 in total):
		a)	Initiation by the Company of phase I clinical trials for the Company’s product in human subjects.
		b)	Initiation by the Company of phase II clinical trials in human subjects.
		c)	Initiation by the Company of phase III clinical trials in human subjects.
	As of August 31, 2014, the Company has not reached any of these milestones.
	On March 27, 2013, the Company signed an agreement with Mintz Levin in which 16% of its fees will be converted to shares of common stock of the Company at market price. On July 14, 2014, $13,395 of fees incurred were converted into 25,759 shares of common stock.
	c.	Pall Life Science Belgium BVBA
	On May 6, 2013, the Israeli Subsidiary entered into a Process Development Agreement with Pall Life Science Belgium BVBA (formerly ATMI BVBA), a Belgian Company which is a wholly-owned subsidiary of Pall Corporation (“Pall”), a U.S. publicly traded company. According to the agreement, Pall will provide services in cell research. The Company will use Pall’s unique technology while the Company will provide to Pall the required materials for purpose of the study. According to the agreement, the Company will pay per achieved phase, as defined in the agreement, with a total consideration of Euro 606,500 for all services. As of August 31, 2014, the Company received services in total value of Euro 360,315.
	d.	Aspen Agency Limited
	On April 3, 2014, the Company entered into a consulting agreement with Aspen Agency Limited, a Hong Kong corporation (“Aspen”), pursuant to which Aspen has agreed to provide investment banking, investor relations and business development services to the Company. In consideration for Aspen’s services, the Company has agreed to issue to Aspen 3,000,000 stock options to acquire shares of the Company’s common stock at an exercise price of $0.52 per share, for a period of three years. The options will be subject to vesting provisions as follows:
		1)	1,000,000 options (the “First Tranche”) will vest as of the date of execution of the agreement; and
		2)	In the event Aspen exercises all 1,000,000 vested First Tranche options during the first 12 months of the agreement, the “Second Tranche” of 2,000,000 options will vest.
	The term of the consulting agreement is from April 3, 2014 and will run for an indefinite period unless terminated by either party providing 30 days written notice.
	The fair value of the First Tranche of the options was determined by using a Monte Carlo model. The fair value of the Second Tranche of the options was determined by using the Black-Scholes valuation model based on the projected values of the Company’s shares of common stock generated by the Monte Carlo simulation model with the following assumptions:
	Fair value of the Company’s shares of common stock:	$	0.51
	Expected life (years):		3-Jan
	Expected stock price volatility:		100%
	Risk free interest rate:		0.11 - 0.95%
	Expected dividend yield:		0.00%
	The fair value of $744,000 was recorded on April 3, 2014 as additional paid-in-capital in the balance sheet with a corresponding expense in general and administrative expenses.
	e.	MaSTherCell SA
	On July 3, 2014, the Company’s Belgian subsidiary, Orgenesis SPRL (the “Belgian Subsidiary”) entered into a service agreement with MaSTherCell SA, a company incorporated in Belgium (“MaSTherCell”), pursuant to which MaSTherCell will conduct certain clinical tests related to diabetes treatment research. The Belgian Subsidiary will pay MaSTherCell for its services Euro 962,500 with 30% payable upon the date of approval of the DGO6 grant (as defined in Note 5b) with the balance being invoiced monthly. Services will commence upon approval of the DG06.
	The term of the service agreement will run until all work is completed or by either party providing 30 days’ written notice of termination.
	f.	Maryland Technology Development Corporation
	On June 30, 2014, the Company’s subsidiary, Orgenesis Maryland, Inc., entered into a grant agreement with Maryland Technology Development Corporation (“TEDCO”). TEDCO was created by the Maryland State Legislature in 1998 to facilitate the transfer and commercialization of technology from Maryland’s research universities and federal labs into the marketplace and to assist in the creation and growth of technology-based businesses in all regions of the State. TEDCO is an independent organization that strives to be Maryland’s lead source for entrepreneurial business assistance and seed funding for the development of startup companies in Maryland’s innovation economy. TEDCO administers the Maryland Stem Cell Research Fund to promote State-funded stem cell research and cures through financial assistance to public and private entities within the State. Under the agreement, TEDCO has agreed to give the subsidiary an amount not to exceed $406,431 (the “Grant”).
	The Grant will be used solely to finance the costs to conduct the research project entitled “Autologous Insulin Producing (AIP) Cells for Diabetes” during a period of two years. On July 22, 2014, the subsidiary received an advance payment of $203,215 on account of the grant. Through August 31, 2014, an amount of $92,537 out of the $203,215 was spent. The amount of grant that was spent through August 31, 2014 was recorded as a deduction of research and development expenses in the statement of operations. The remaining $110,678 is presented on the balance sheet as of August 31, 2014 among current liabilities.

STOCKHOLDERS_CAPITAL_DEFICIENC

STOCKHOLDERS CAPITAL DEFICIENCY	9 Months Ended
	Aug. 31, 2014
STOCKHOLDERS CAPITAL DEFICIENCY [Text Block]	'
	NOTE 4 – STOCKHOLDERS’ CAPITAL DEFICIENCY
	a.	Share Capital
	The Company’s common shares are traded on the OTC Market Group’s OTCQB under the symbol “ORGS”.
	b.	Financings
		1)	In April and July 2012, the Company completed a private placement with Derby Management, LLC (“Derby”) for a total consideration of $1,100,000 for 1,100,000 shares of common stock and 1,100,000 warrants.
		2)	In December 2012, the Company entered into a subscription agreement with Derby for the issuance of 500,000 units for a total consideration of $500,000. Each unit is comprised of one share of the Company’s common stock and two non-transferrable warrants (See also Note 6). In connection with this agreement, the 1,000,000 warrants issued to Derby were cancelled in July 2013.
		3)	In May 2013, the Company entered into a subscription agreement with Pall, pursuant to which Pall purchased 1,526,718 units at a price of $0.8515 per unit for total consideration of $1,300,000. Each unit consisted of one share of the Company’s common stock and one warrant (See also Note 6). On March 28, 2014, on June 11, 2014 and on July 31, 2014, the Company filed prospectuses pursuant to Rule 424(b)(3), which are part of a registration statement filed by the Company with the SEC, covering the shares under the subscription agreement, which allows Pall to sell the shares (including shares that will be issued to Pall as a result of the exercise of the warrants).
		4)	On December 13, 2013, the Company entered into a $3,000,000 common stock purchase agreement with Kodiak Capital Group, LLC, a Newport Beach-based institutional investor (“Kodiak”). The purchase agreement is conditioned, among other things, by filing a registration statement with the SEC covering the shares that may be issued to Kodiak under the terms of the common stock purchase agreement. After the SEC has declared the registration statement related to the transaction effective (March 18, 2014; See below), the Company has the right at its sole discretion over a period of one year to sell shares of common stock under the terms set forth in the agreement in the total amount of up to $3,000,000. Proceeds from this transaction will be used to fund research and development and working capital. Pursuant to the common stock purchase agreement, the Company issued to Kodiak 250,000 shares of common stock of the Company at no consideration. The Company valued the shares at their fair value of $135,000 and recorded the charge as financing cost. The Company’s ability to put shares to Kodiak and obtain funds under the equity line is limited by the terms and conditions in the common stock purchase agreement, including restrictions on when the Company may exercise its put rights, restrictions on the amount the Company may put to Kodiak at any one time, which is determined in part by the trading volume of the Company’s common stock, and a limitation on its ability to put shares to Kodiak.
		5)	During the first quarter of 2014, the Company issued 1,128,849 units in a non-brokered private placement for total consideration of $587,001. Each unit consisted of one share of the Company’s common stock and one non- transferable common share purchase warrant, with each warrant entitling the holder to acquire one additional share of the Company’s common stock at an exercise price of $0.52 per share for a period of three years. The fair value of these warrants as of the date of issuance was $393,411 using the Black-Scholes valuation model based on the following assumptions: dividend yield of 0% for all years; expected volatility of 117%; risk free interest of 0.68%, and an expected life of three years.
		6)	On April 24, 2014, the Company issued 384,615 units at a purchase price of $0.52 to one investor in a non- brokered private placement for a total consideration of $200,000. Each unit consisted of one share of the Company’s common stock and one non-transferable common share purchase warrant, with each warrant entitling the holder to acquire one additional share of the Company’s common stock at an exercise price of $0.52 per share for a period of three years. The fair value of these warrants as of the date of issuance was $117,047 using the Black- Scholes valuation model based on the following assumptions: dividend yield of 0% for all years; expected volatility of 102%; risk free interest of 0.91%, and an expected life of three years.
		7)	On June 30, 2014, the Company entered into a debt settlement agreement with one creditor, whereby it settled a debt in the amount of $24,011 by the issuance of 46,175 share of its common stock at a price per share of $0.52. On July 14, 2014, the Company entered into a debt settlement agreement with another creditor, whereby it settled a debt in the amount of $13,395 by the issuance of 25,759 shares of its common stock at a price per share of $0.52.
		8)	In July 2014, one of the investors mentioned in Note 4b(5) above exercised warrants to purchase 96,154 shares of the Company’s common stock at an exercise price of $0.52 for a total consideration of $50,000. As an inducement to the investor to exercise the warrants, the Company issued the investor twice the number of warrants exercised, or 192,308 new warrants, with each warrant entitling the holder to acquire one additional share of the Company’s common stock at an exercise price of $0.52 per share for a period of three years. The fair value of these warrants as of the date of issuance was $60,023 using the Black-Scholes valuation model based on the following assumptions: dividend yield of 0% for all years; expected volatility of 103%; risk free interest of 0.98%, and an expected life of three years.
		9)	In July 2014, the Company issued 144,230 units at a purchase price of $0.52 per unit to one investor in a non-brokered private placement for total consideration of $75,000. Each unit consisted of one share of the Company’s common stock and one non-transferable common share purchase warrant, with each warrant entitling the holder to acquire one additional share of the Company’s common stock at an exercise price of $0.52 per share for a period of three years. The fair value of these warrants as of the date of issuance was $45,172 using the Black- Scholes valuation model based on the following assumptions: dividend yield of 0% for all years; expected volatility of 103%; risk free interest of 0.95%, and an expected life of three years.
		10)	In August 2014, the Company issued 115,385 units at a purchase price of $0.52 per unit to one investor in a non-brokered private placement for total consideration of $60,000. Each unit consisted of one share of the Company’s common stock and one non-transferable common share purchase warrant, with each warrant entitling the holder to acquire one additional share of the Company’s common stock at an exercise price of $0.52 per share for a period of three years. The fair value of these warrants as of the date of issuance was $43,300 using the Black- Scholes valuation model based on the following assumptions: dividend yield of 0% for all years; expected volatility of 102%; risk free interest of 0.93%, and an expected life of three years.
	On March 28, 2014 and on June 11, 2014, the Company filed prospectuses pursuant to Rule 424(b)(3), which are part of a registration statement filed by the Company with the SEC. Under the prospectuses, the selling stockholders identified in the prospectuses may offer and sell up to 10,603,436 shares of the Company’s common stock, which will consist of: (i) up to 250,000 shares of common stock issued or to be issued to Kodiak as commitment shares pursuant to common stock purchase agreement dated December 13, 2013 (See Note 4b(4) above) and up to 7,300,000 shares of common stock to be sold by Kodiak pursuant to the common stock purchase agreement; (ii) 1,526,718 shares of common stock issued to Pall ; and (iii) up to 1,526,718 shares of common stock that may be issued upon the exercise of warrants issued to Pall. The 7,550,000 shares of common stock registered for resale by Kodiak represents 14% of the Company’s issued and outstanding shares of common stock as of March 5, 2014. The selling stockholders may sell all or a portion of the shares being offered pursuant to the prospectuses at fixed prices, at prevailing market prices at the time of sale, at varying prices or at negotiated prices.
	c.	Stock-Based Compensation
	During the three months ended August 31, 2014, the Company granted an aggregate of 3,137,300 options to its employees and consultants.
	Options Granted to Employees
		1)	On August 1, 2014, the Company granted an aggregate of 200,000 stock options to an employee that are exercisable at $0.50 per share, with 50,000 vesting quarterly over one year. The fair value of these options as of the date of grant was $80,531 using the Black and Scholes option-valuation model. In addition, the Company granted an aggregate of 200,000 stock options to an employee that are exercisable at $0.50 per share, with 25,000 vesting quarterly over two years. The fair value of these options as of the date of grant was $96,058 using the Black and Scholes option-valuation model.
		2)	On August 22, 2014, the Company granted an aggregate of 2,762,250 stock options to the Company’s Chief Executive Officer that are exercisable at $0.0001 per share. Out of the total granted, 414,304 options vested immediately with a fair value as of the date of grant of $260,981 using the Black and Scholes option-valuation model, 1,242,996 options will vest quarterly over 4 years, with a fair value as of the date of grant of $782,997 using the Black and Scholes option-valuation model, and 1,104,950 options will vest based on certain performance criteria.
	The fair value of the options on the date of grant was computed using the Black-Scholes model. The underlying data used for computing the fair value of the options are mainly as follows:
			Three Months
			Ended
			31-Aug-14
	Value of one common share	$	0.53 - 0.63
	Dividend yield		0%
	Expected stock price volatility		101%
	Risk free interest rate		1.67 - 2.52%
	Expected term (years)		10-May
	Options Granted to Consultants
	On August 1, 2014, the Company granted an aggregate of 1,080,000 stock options to a consultant that are exercisable at $0.50, with 216,000 vesting immediately and 216,000 for each of the next four years. The fair value of these options as of the date of grant was $403,614 using the Black and Scholes option-valuation model. The underlying data used for computing the fair value of the options are mainly as follows:
			Three Months
			Ended
			31-Aug-14
	Value of one common share	$	0.53
	Dividend yield		0%
	Expected stock price volatility		101%
	Risk free interest rate		1.31%
	Expected term (years)		4

CONVERIBLE_LOAN_AGREEMENTS

CONVERIBLE LOAN AGREEMENTS	9 Months Ended
	Aug. 31, 2014
CONVERIBLE LOAN AGREEMENTS [Text Block]	'
	NOTE 5 – CONVERTIBLE LOAN AGREEMENTS
	a.	Mediapark A.G.
	In March 2013, the Company entered into a loan and warrant subscription agreement with Mediapark A.G., a Marshall Islands Company (“Mediapark”). The Company received a loan (the “Mediapark Loan”) in the total amount of $250,000 and issued to Mediapark 100,000 warrants. Each warrant can be exercised into one share of common stock at a purchase price of $0.50 per share and is exercisable until March 22, 2015. See also Note 6. The warrants issued are detachable from the Mediapark Loan and classified as a liability due to down-round protection (ratchet and anti-dilution provisions). Therefore the Company allocated the proceeds from Mediapark, first to the warrants based upon their fair value and the residual amount was allocated to the Mediapark Loan. As of the issuance day of the warrants, the fair value of the warrants was $65,192 based on Monte Carlo valuation-model. See also Note 6.
	The Mediapark Loan bears interest at an annual rate of 8%, which is calculated quarterly. The original maturity day of the Mediapark Loan was June 30, 2013. The Company had the right to extend the maturity date for an additional period of up to 90 days provided that it issues an additional 100,000 warrants (the “Additional Warrants”).
	If the Company has not paid the Mediapark Loan in full at the maturity date or, if extended, at the extended maturity date, Mediapark has the right of conversion in respect of the total outstanding amount of the principal balance including accrued interest as of the conversion date into shares of common stock, at a price per share equal to the lower of: (i) $0.75, and (ii) the value of the weighted average price of the share during the five trading days prior to the date of conversion.
	On June 30, 2013 the Company exercised its discretion to extend the maturity date of the Mediapark Loan to September 30, 2013, In return for extending the maturity date, the Company issued to Mediapark additional warrants at an exercise price of $0.50 per share. The fair value of the warrants was $48,800 based on Monte Carlo valuation-model. See also Note 6.
	On September 30, 2013, the Company extended again the maturity date of Mediapark Loan to December 31, 2013. In return for extending the maturity date, the Company issued to Mediapark 100,000 warrants, which can be exercised into shares at an exercise price of $0.50 per share until September 30, 2015. The fair value of the warrants was $46,000 based on Monte Carlo valuation-model. See also Note 6.
	On December 6, 2013, the Company entered into an amendment of the Mediapark Loan, pursuant to which Mediapark purchased an 8% unsecured convertible debenture (the “Mediapark Convertible Loan”) in the aggregate principal amount of $100,000. Interest is calculated semi-annually and is payable, along with the principal, on or before December 6, 2014. According to the agreement, in the event that the Company completes an equity financing prior to the maturity date for gross proceeds of $350,000 or more, Mediapark will convert the Company’s indebtedness under the Mediapark Loan and the Mediapark Convertible loan into shares of common stock and/or warrants on the same terms as the new equity financing.
	As a result of the issuance of 1,128,849 units described in Note 4b(5), the Mediapark Loan and the Convertible Loan described above in the aggregate amount of $370,772 (including principal and interest) outstanding as of March 3, 2014 were converted on that date to 713,023 shares of common stock of the Company at a conversion rate of $0.52 per share and to 713,023 warrants to acquire additional shares of the Company’s common stock at an exercise price of $0.52 per share for a period of three years. The fair value of these warrants as of the date of issuance was $259,731 using the Black-Scholes valuation model based on the following assumptions: dividend yield of 0% for all years; expected volatility of 117%; risk free interest of 0.66%, and an expected life of three years.
	b.	Nine Investments Limited
	On May 29, 2014, the Company entered into a convertible loan agreement with Nine Investments Limited, a Hong Kong company (“Nine Investments”), pursuant to which Nine Investments loaned the Company $1,500,000 which the Company subsequently transferred to its Belgian subsidiary, Orgenesis SPRL, to fund a research project to develop new medical technologies and cell therapies for the treatment of diabetes. The Company received the funds on June 4, 2014 (the “Closing Date”). Interest is calculated at 8% semi-annually and is payable, along with the principal on or before December 31, 2014 subject to acceleration for specific events including: (i) if a grant of money to Orgenesis SPRL is not approved by Department De La Gestion Financiere Direction De L’analyse Financiere (“DGO6”) within 90 days after the loan proceeds are advanced; and (ii) if the Company raises, in the aggregate, gross proceeds of more than $400,000 between the date of the loan and the maturity date, but only to the extent of gross proceeds so raised that are in excess of $400,000.
	Nine Investments may provide the Company with written notice to convert all or part of the loan into shares of its common stock at $0.40 per share. The conversion price and the number of shares of common stock deliverable upon the conversion of the loan shall be subject to adjustment in the event and in the manner following: (i) if and whenever the Company’s common shares at any time outstanding shall be subdivided into a greater or consolidated into a lesser number of common shares, or in case of any capital reorganization or of any reclassification of the capital of the Company or in case of the consolidation, merger or amalgamation of the Company with or into any other company or of the sale of the assets of the Company as or substantially as an entirety or of any other company, the conversion price shall be decreased or increased proportionately; and (ii) in the event the Company issues any shares of common stock or securities convertible into shares at a price less than the conversion price, the conversion price shall be reduced for any unpaid or unconverted loan amount to the new issuance price.
	As consideration for entering into the loan agreement, on June 5, 2014, the Company issued to Nine Investments 500,000 shares of its common stock.
	The Company allocated the proceeds from Nine Investments between the shares and the convertible loan based on the relative fair value. In addition, the conversion right is detachable from the loan and classified as a derivative due to down-round protection (full ratchet and anti-dilution provisions). Therefore, the Company attributed, to the conversion right derivative, out of the proceeds allocated to the convertible loan based on its fair value. The allocation of conversion right and bonus shares represents a discount to the loan and will be accreted until the maturity date of the loan (December 31, 2014).
	The table below presents the fair value of the instruments issued as of the Closing Date and the allocation of the proceeds:
			Total Fair		Allocation of
			Value		Proceeds
	Loan component	$	1,262,000	$	746,000
	Bonus shares component		250,000		180,000
	Embedded derivative component		574,000		574,000
	Total	$	2,086,000	$	1,500,000
	The bonus shares component was recorded as additional paid-in-capital and the fair value of the embedded derivative component is classified as a financial liability because the conversion price and the number of shares of common stock deliverable upon the conversion of the loan shall be subject to adjustment and will be measured in subsequent periods at fair value with changes in fair value charged to financial expenses or income, net. Due to the difference between the amounts actually owed to the lender and the presentation of the loan in the financial statement, the loan was measured, subsequent to its initial recognition, at amortized cost on the basis of the effective interest method over the loan period.

WARRANTS

WARRANTS	9 Months Ended
	Aug. 31, 2014
WARRANTS [Text Block]	'
	NOTE 6 – WARRANTS
	As part of the Company’s private placements and loan received as described in Notes 4 and 5, the Company issued warrants, as follows:
	a.	Warrants Which are Subject to Exercise Price Adjustments
		1)	In December 2012, the Company issued 1,000,000 non-transferable warrants. Each warrant can be exercised into one share of common stock at an exercise price of $0.50 per share and is exercisable until November 30, 2014. In the event the Company will issue any shares of common stock or securities convertible into shares of common stock at a price less than $0.50, the exercise price shall be reduced to the new issuance price.
		2)	In March 2013, the Company issued 100,000 warrants in connection with the loan and warrant subscription agreement with Mediapark (see Note 5a). Each warrant can be exercised into one share of common stock at an exercise price of $0.50 per share and is exercisable until March 22, 2015. In the event the Company issues any shares of common stock or securities convertible into shares of common stock at a price less than $0.50, the exercise price shall be reduced to the new issuance price.
		3)	In May 2013, the Company issued 1,526,718 warrants. Each warrant can be exercised into one share of common stock at an exercise price of $1.00 per share and is exercisable until May 6, 2015. In the event the Company issues any shares of common stock or securities convertible into shares of common stock at a price less than $0.8515, the exercise price shall be reduced to the new issuance price. As a result of the issuance of 1,128,849 warrants during the second quarter of 2014, the exercise price of those warrants was reduced to $0.52 per share.
		4)	On June 30, 2013, the Company exercised its discretion to extend the maturity date of the Mediapark Loan from September 30, 2013. In return for extending the maturity date, the Company issued to Mediapark 100,000 additional warrants at an exercise price of $0.50 per share until June 30, 2015. In the event the Company issues any shares of common stock or securities convertible into shares of common stock at a price less than $0.50, the exercise price shall be reduced to the new issuance price (See also Note 5).
		5)	On September 30, 2013, the Company exercised its discretion to extend the maturity date of the Mediapark loan from December 31, 2013. In return for extending the maturity date, the Company issued to Mediapark 100,000 additional warrants, which can be exercised into shares at an exercise price of $0.50 per share until September 30, 2015. In the event the Company issues any shares of common stock or securities convertible into shares of common stock at a price less than $0.50, the exercise price shall be reduced to the new issuance price (See also Note 5).
	b.	Warrants Which are Not Subject to Exercise Price Adjustments
		1)	In April 2012, the Company issued 100,000 non-transferable warrants. Each warrant can be exercised into one share of common stock at an exercise price of $1.00 per share and is exercisable until November 30, 2014.
		2)	In March 2014, the Company issued 1,128,849 warrants. Each warrant can be exercised into one share of common stock at an exercise price of $0.52 per share and is exercisable until March 2017. In July 2014, 96,154 warrants were exercised (See Note 4b8).
		3)	On March 3, 2014, as a result of the conversion of the Mediapark loans, the Company issued to Mediapark 713,023 warrants. Each warrant can be exercised into one share of common stock at an exercise price of $0.52 per share and is exercisable until March 3, 2017 (See also Note 5).
		4)	On April 24, 2014, the Company issued 384,615 warrants. Each warrant can be exercised into one share of common stock at an exercise price of $0.52 per share and is exercisable until April 24, 2017.
		5)	In July 2014, the Company issued 336,538 warrants. Each warrant can be exercised into one share of common stock at an exercise price of $0.52 per share and is exercisable until July 2017.
		6)	In August 2014, the Company issued 115,385 warrants. Each warrant can be exercised into one share of common stock at an exercise price of $0.52 per share and is exercisable until August 2017.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Aug. 31, 2014
SUBSEQUENT EVENTS [Text Block]	'
	NOTE 7 – SUBSEQUENT EVENTS
	On September 1, 2014, the Company entered into a convertible loan agreement for $50,000. The loan bears an annual interest rate of 6% and matures on February 28, 2015, unless converted earlier. The lender shall have the right to convert all or any portion of the outstanding principal amount and all accrued but unpaid interest thereon into shares of common stock of the Company at a conversion price of $0.40 per share.
	On September 1, 2014, the Company granted 650,000 stock options to an employee that are exercisable at $0.50 per share and vest quarterly over 4 years.
	On September 15, 2014, the Company entered into a convertible loan agreement for $100,000. The loan bears an annual interest rate of 6% and matures on March 15, 2015, unless converted earlier. The lender shall have the right to convert all or any portion of the outstanding principal amount and all accrued but unpaid interest thereon into shares of common stock of the Company at a conversion price of $0.40 per share.

FAIR_VALUE_PRESENTATION_Tables

FAIR VALUE PRESENTATION (Tables)	9 Months Ended							12 Months Ended
	Aug. 31, 2014							Nov. 30, 2013
Schedule of Assets and Liabilities at Fair Value [Table Text Block]	'							'
			31-Aug-14							30-Nov-13
			Level 3			Total				Level 3		Total
	Warrants	$	1,435,000		$	1,435,000		Warrants	$	1,157,954	$	1,157,954
	Embedded derivative*	$	1,588,000		$	1,588,000
Schedule of Fair Value, Assumptions Used [Table Text Block]	'							'
							Embedded
				Warrants			Derivative
		Fair value of shares of common stock	$	0.9		$	0.9
		Expected volatility		90%			86%
		Risk free interest rate		0.03% - 0.12%			0.04%
		Expected term (years)		0.25 – 1.08			0.33
		Expected dividend yield		0%			0%
Schedule of Fair Value of Financial Liabilities, Activity [Table Text Block]	'							'
							Embedded
				Warrants			Derivative
		Balance at beginning of period	$	1,157,954		$	-
		Additions		-			574,000
		Changes in fair value during the period		277,046			1,014,000
		Balance at end of period	$	1,435,000		$	1,588,000

STOCKHOLDERS_CAPITAL_DEFICIENC1

STOCKHOLDERS CAPITAL DEFICIENCY (Tables)	9 Months Ended
	Aug. 31, 2014
Schedule of Fair Value Asumptions, Stock Options [Table Text Block]	'
			Three Months
			Ended
			31-Aug-14
	Value of one common share	$	0.53 - 0.63
	Dividend yield		0%
	Expected stock price volatility		101%
	Risk free interest rate		1.67 - 2.52%
	Expected term (years)		10-May
Schedule of Fair Value Assumptions, Options Granted to Consultants [Table Text Block]	'
			Three Months
			Ended
			31-Aug-14
	Value of one common share	$	0.53
	Dividend yield		0%
	Expected stock price volatility		101%
	Risk free interest rate		1.31%
	Expected term (years)		4

CONVERIBLE_LOAN_AGREEMENTS_Tab

CONVERIBLE LOAN AGREEMENTS (Tables)	9 Months Ended
	Aug. 31, 2014
Schedule of Fair Value of Loan Agreement [Table Text Block]	'
			Total Fair		Allocation of
			Value		Proceeds
	Loan component	$	1,262,000	$	746,000
	Bonus shares component		250,000		180,000
	Embedded derivative component		574,000		574,000
	Total	$	2,086,000	$	1,500,000

GENERAL_AND_BASIS_OF_PRESENTAT1

GENERAL AND BASIS OF PRESENTATION (Narrative) (Details) (USD $)	9 Months Ended
	Aug. 31, 2014
General And Basis Of Presentation 1	$16,672,542

COMMITMENTS_AND_CONTINGENT_LIA1

COMMITMENTS AND CONTINGENT LIABILITIES (Narrative) (Details) (USD $)	9 Months Ended
	Aug. 31, 2014
	M
	D
Commitments And Contingent Liabilities 1	3.50%
Commitments And Contingent Liabilities 2	16.00%
Commitments And Contingent Liabilities 3	$15,000
Commitments And Contingent Liabilities 4	50,000
Commitments And Contingent Liabilities 5	50,000
Commitments And Contingent Liabilities 6	150,000
Commitments And Contingent Liabilities 7	750,000
Commitments And Contingent Liabilities 8	2,000,000
Commitments And Contingent Liabilities 9	150,000,000
Commitments And Contingent Liabilities 10	5,563,809
Commitments And Contingent Liabilities 11	1,000
Commitments And Contingent Liabilities 12	74,000
Commitments And Contingent Liabilities 13	92,000
Commitments And Contingent Liabilities 14	114,000
Commitments And Contingent Liabilities 15	80,000
Commitments And Contingent Liabilities 16	1,390,952
Commitments And Contingent Liabilities 17	509,622
Commitments And Contingent Liabilities 18	34.57%
Commitments And Contingent Liabilities 19	50,000
Commitments And Contingent Liabilities 20	20,000
Commitments And Contingent Liabilities 21	50,000
Commitments And Contingent Liabilities 22	16.00%
Commitments And Contingent Liabilities 23	13,395
Commitments And Contingent Liabilities 24	25,759
Commitments And Contingent Liabilities 25	606,500
Commitments And Contingent Liabilities 26	360,315
Commitments And Contingent Liabilities 27	3,000,000
Commitments And Contingent Liabilities 28	$0.52
Commitments And Contingent Liabilities 29	1,000,000
Commitments And Contingent Liabilities 30	1,000,000
Commitments And Contingent Liabilities 31	12
Commitments And Contingent Liabilities 32	2,000,000
Commitments And Contingent Liabilities 33	30
Commitments And Contingent Liabilities 34	744,000
Commitments And Contingent Liabilities 35	962,500
Commitments And Contingent Liabilities 36	30.00%
Commitments And Contingent Liabilities 37	30
Commitments And Contingent Liabilities 38	406,431
Commitments And Contingent Liabilities 21	203,215
Commitments And Contingent Liabilities 22	92,537
Commitments And Contingent Liabilities 23	203,215
Commitments And Contingent Liabilities 24	$110,678

STOCKHOLDERS_CAPITAL_DEFICIENC2

STOCKHOLDERS CAPITAL DEFICIENCY (Narrative) (Details) (USD $)	9 Months Ended
	Aug. 31, 2014
	Y
Stockholders Capital Deficiency 1	$1,100,000
Stockholders Capital Deficiency 2	1,100,000
Stockholders Capital Deficiency 3	1,100,000
Stockholders Capital Deficiency 4	500,000
Stockholders Capital Deficiency 5	500,000
Stockholders Capital Deficiency 6	1,000,000
Stockholders Capital Deficiency 7	1,526,718
Stockholders Capital Deficiency 8	$0.85
Stockholders Capital Deficiency 9	1,300,000
Stockholders Capital Deficiency 10	3,000,000
Stockholders Capital Deficiency 11	3,000,000
Stockholders Capital Deficiency 12	250,000
Stockholders Capital Deficiency 13	135,000
Stockholders Capital Deficiency 14	1,128,849
Stockholders Capital Deficiency 15	587,001
Stockholders Capital Deficiency 16	$0.52
Stockholders Capital Deficiency 17	393,411
Stockholders Capital Deficiency 18	0.00%
Stockholders Capital Deficiency 19	117.00%
Stockholders Capital Deficiency 20	0.68%
Stockholders Capital Deficiency 21	384,615
Stockholders Capital Deficiency 22	0.52
Stockholders Capital Deficiency 23	200,000
Stockholders Capital Deficiency 24	$0.52
Stockholders Capital Deficiency 25	117,047
Stockholders Capital Deficiency 26	0.00%
Stockholders Capital Deficiency 27	102.00%
Stockholders Capital Deficiency 28	0.91%
Stockholders Capital Deficiency 29	24,011
Stockholders Capital Deficiency 30	46,175
Stockholders Capital Deficiency 31	0.52
Stockholders Capital Deficiency 32	13,395
Stockholders Capital Deficiency 33	25,759
Stockholders Capital Deficiency 34	0.52
Stockholders Capital Deficiency 35	96,154
Stockholders Capital Deficiency 36	0.52
Stockholders Capital Deficiency 37	50,000
Stockholders Capital Deficiency 38	192,308
Stockholders Capital Deficiency 39	$0.52
Stockholders Capital Deficiency 40	60,023
Stockholders Capital Deficiency 41	0.00%
Stockholders Capital Deficiency 42	103.00%
Stockholders Capital Deficiency 43	0.98%
Stockholders Capital Deficiency 44	144,230
Stockholders Capital Deficiency 45	$0.52
Stockholders Capital Deficiency 46	75,000
Stockholders Capital Deficiency 47	$0.52
Stockholders Capital Deficiency 48	45,172
Stockholders Capital Deficiency 49	0.00%
Stockholders Capital Deficiency 50	103.00%
Stockholders Capital Deficiency 51	0.95%
Stockholders Capital Deficiency 52	115,385
Stockholders Capital Deficiency 53	$0.52
Stockholders Capital Deficiency 54	60,000
Stockholders Capital Deficiency 55	$0.52
Stockholders Capital Deficiency 56	43,300
Stockholders Capital Deficiency 57	0.00%
Stockholders Capital Deficiency 58	102.00%
Stockholders Capital Deficiency 59	0.93%
Stockholders Capital Deficiency 60	10,603,436
Stockholders Capital Deficiency 61	250,000
Stockholders Capital Deficiency 62	7,300,000
Stockholders Capital Deficiency 63	1,526,718
Stockholders Capital Deficiency 64	1,526,718
Stockholders Capital Deficiency 65	7,550,000
Stockholders Capital Deficiency 66	14.00%
Stockholders Capital Deficiency 67	3,137,300
Stockholders Capital Deficiency 68	200,000
Stockholders Capital Deficiency 69	$0.50
Stockholders Capital Deficiency 70	50,000
Stockholders Capital Deficiency 71	80,531
Stockholders Capital Deficiency 72	200,000
Stockholders Capital Deficiency 73	$0.50
Stockholders Capital Deficiency 74	25,000
Stockholders Capital Deficiency 75	96,058
Stockholders Capital Deficiency 76	2,762,250
Stockholders Capital Deficiency 77	$0.00
Stockholders Capital Deficiency 78	414,304
Stockholders Capital Deficiency 79	260,981
Stockholders Capital Deficiency 80	1,242,996
Stockholders Capital Deficiency 81	4
Stockholders Capital Deficiency 82	782,997
Stockholders Capital Deficiency 83	1,104,950
Stockholders Capital Deficiency 84	1,080,000
Stockholders Capital Deficiency 85	0.5
Stockholders Capital Deficiency 86	216,000
Stockholders Capital Deficiency 87	216,000
Stockholders Capital Deficiency 88	$403,614

CONVERIBLE_LOAN_AGREEMENTS_Nar

CONVERIBLE LOAN AGREEMENTS (Narrative) (Details) (USD $)	9 Months Ended
	Aug. 31, 2014
	D
Converible Loan Agreements 1	$250,000
Converible Loan Agreements 2	100,000
Converible Loan Agreements 3	$0.50
Converible Loan Agreements 4	65,192
Converible Loan Agreements 5	8.00%
Converible Loan Agreements 6	90
Converible Loan Agreements 7	100,000
Converible Loan Agreements 8	0.75
Converible Loan Agreements 9	$0.50
Converible Loan Agreements 10	48,800
Converible Loan Agreements 11	100,000
Converible Loan Agreements 12	$0.50
Converible Loan Agreements 13	46,000
Converible Loan Agreements 14	8.00%
Converible Loan Agreements 15	100,000
Converible Loan Agreements 16	350,000
Converible Loan Agreements 17	1,128,849
Converible Loan Agreements 18	370,772
Converible Loan Agreements 19	713,023
Converible Loan Agreements 20	$0.52
Converible Loan Agreements 21	713,023
Converible Loan Agreements 22	$0.52
Converible Loan Agreements 23	259,731
Converible Loan Agreements 24	0.00%
Converible Loan Agreements 25	117.00%
Converible Loan Agreements 26	0.66%
Converible Loan Agreements 27	1,500,000
Converible Loan Agreements 28	8.00%
Converible Loan Agreements 29	90
Converible Loan Agreements 30	400,000
Converible Loan Agreements 31	$400,000
Converible Loan Agreements 32	$0.40
Converible Loan Agreements 33	500,000

WARRANTS_Narrative_Details

WARRANTS (Narrative) (Details) (USD $)	9 Months Ended
	Aug. 31, 2014
Warrants 1	1,000,000
Warrants 2	$0.50
Warrants 3	$0.50
Warrants 4	100,000
Warrants 5	$0.50
Warrants 6	0.5
Warrants 7	1,526,718
Warrants 8	$1
Warrants 9	0.8515
Warrants 10	1,128,849
Warrants 11	$0.52
Warrants 12	100,000
Warrants 13	$0.50
Warrants 14	0.5
Warrants 15	100,000
Warrants 16	$0.50
Warrants 17	$0.50
Warrants 18	100,000
Warrants 19	$1
Warrants 20	1,128,849
Warrants 21	$0.52
Warrants 22	96,154
Warrants 23	713,023
Warrants 24	$0.52
Warrants 25	384,615
Warrants 26	$0.52
Warrants 27	336,538
Warrants 28	$0.52
Warrants 29	115,385
Warrants 30	$0.52

SUBSEQUENT_EVENTS_Narrative_De

SUBSEQUENT EVENTS (Narrative) (Details) (USD $)	9 Months Ended
	Aug. 31, 2014
	Y
Subsequent Events 1	$50,000
Subsequent Events 2	6.00%
Subsequent Events 3	$0.40
Subsequent Events 4	650,000
Subsequent Events 5	$0.50
Subsequent Events 6	4
Subsequent Events 7	$100,000
Subsequent Events 8	6.00%
Subsequent Events 9	$0.40

Schedule_of_Assets_and_Liabili

Schedule of Assets and Liabilities at Fair Value (Details) (USD $)	9 Months Ended	12 Months Ended
	Aug. 31, 2014	Nov. 30, 2013
Fair Value Presentation Schedule Of Assets And Liabilities At Fair Value 1	$1,435,000	'
Fair Value Presentation Schedule Of Assets And Liabilities At Fair Value 2	1,435,000	'
Fair Value Presentation Schedule Of Assets And Liabilities At Fair Value 3	1,588,000	'
Fair Value Presentation Schedule Of Assets And Liabilities At Fair Value 4	1,588,000	'
Fair Value Presentation Schedule Of Assets And Liabilities At Fair Value 1	'	1,157,954
Fair Value Presentation Schedule Of Assets And Liabilities At Fair Value 2	'	$1,157,954

Schedule_of_Fair_Value_Assumpt

Schedule of Fair Value, Assumptions Used (Details)	9 Months Ended
	Aug. 31, 2014
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 1	0.9
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 2	0.9
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 3	90.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 4	86.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 5	0.03%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 6	0.12%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 7	0.04%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 8	0.25
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 9	1.08
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 10	0.33
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 11	0.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 12	0.00%

Schedule_of_Fair_Value_of_Fina

Schedule of Fair Value of Financial Liabilities, Activity (Details) (USD $)	9 Months Ended
	Aug. 31, 2014
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 1	$1,157,954
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 2	0
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 3	0
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 4	574,000
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 5	277,046
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 6	1,014,000
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 7	1,435,000
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 8	$1,588,000

Schedule_of_Fair_Value_Asumpti

Schedule of Fair Value Asumptions, Stock Options (Details) (USD $)	9 Months Ended
	Aug. 31, 2014
Stockholders Capital Deficiency Schedule Of Fair Value Asumptions, Stock Options 1	0.53
Stockholders Capital Deficiency Schedule Of Fair Value Asumptions, Stock Options 2	0.63
Stockholders Capital Deficiency Schedule Of Fair Value Asumptions, Stock Options 3	0.00%
Stockholders Capital Deficiency Schedule Of Fair Value Asumptions, Stock Options 4	101.00%
Stockholders Capital Deficiency Schedule Of Fair Value Asumptions, Stock Options 5	1.67
Stockholders Capital Deficiency Schedule Of Fair Value Asumptions, Stock Options 6	2.52%
Stockholders Capital Deficiency Schedule Of Fair Value Asumptions, Stock Options 7	$5
Stockholders Capital Deficiency Schedule Of Fair Value Asumptions, Stock Options 8	$10

Schedule_of_Fair_Value_Assumpt1

Schedule of Fair Value Assumptions, Options Granted to Consultants (Details) (USD $)	9 Months Ended
	Aug. 31, 2014
Stockholders Capital Deficiency Schedule Of Fair Value Assumptions, Options Granted To Consultants 1	0.53
Stockholders Capital Deficiency Schedule Of Fair Value Assumptions, Options Granted To Consultants 2	0.00%
Stockholders Capital Deficiency Schedule Of Fair Value Assumptions, Options Granted To Consultants 3	101.00%
Stockholders Capital Deficiency Schedule Of Fair Value Assumptions, Options Granted To Consultants 4	1.31%
Stockholders Capital Deficiency Schedule Of Fair Value Assumptions, Options Granted To Consultants 5	$4

Schedule_of_Fair_Value_of_Loan

Schedule of Fair Value of Loan Agreement (Details) (USD $)	9 Months Ended
	Aug. 31, 2014
Converible Loan Agreements Schedule Of Fair Value Of Loan Agreement 1	$1,262,000
Converible Loan Agreements Schedule Of Fair Value Of Loan Agreement 2	746,000
Converible Loan Agreements Schedule Of Fair Value Of Loan Agreement 3	250,000
Converible Loan Agreements Schedule Of Fair Value Of Loan Agreement 4	180,000
Converible Loan Agreements Schedule Of Fair Value Of Loan Agreement 5	574,000
Converible Loan Agreements Schedule Of Fair Value Of Loan Agreement 6	574,000
Converible Loan Agreements Schedule Of Fair Value Of Loan Agreement 7	2,086,000
Converible Loan Agreements Schedule Of Fair Value Of Loan Agreement 8	$1,500,000